Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review
- PMID: 32104553
- PMCID: PMC7031144
- DOI: 10.4251/wjgo.v12.i2.228
Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review
Abstract
Background: Liver metastases secondary to breast cancer are associated with unfavourable prognosis. Radioembolization with ytrrium-90 is an emerging option for management of liver metastases of breast cancer when other systemic therapies have failed to achieve disease control. However, unlike the case of other liver tumours (colorectal/melanoma metastases/cholangiocarcinoma), its role in the management of breast liver metastases is yet to be elucidated.
Aim: The aims of this systematic review were to (1) assess the effect of radioembolization with yttrium-90 on tumour response; and (2) to estimate patient survival post radioembolization.
Methods: The review was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. A systematic literature search was performed using the PubMed and EMBASE databases from January 2007 to December 2018. The initial search yielded 265 reports which were potentially suitable for inclusion in this review. Studies published in English reporting at least one outcome of interest were considered to be suitable for inclusion. Conference abstracts; case reports, animal studies and reports not published in English were excluded from this review. Data was retrieved from each individual report on the name of primary author, year of publication, patient demographics, type of microspheres used, radiation dose delivered to tumour, duration of follow-up, disease control rate (%), tumour response, and overall patient survival.
Results: The final number of studies which met the inclusion criteria was 12 involving 452 patients. There were no randomized controlled trials identified after the literature search. The age of the patients included in this review ranged from 52 to 61 years. The duration of the follow up period post-radioembolization ranged from 6 to 15.7 mo. The total number of patients with breast metastases not confined to the liver was 236 (52.2%). Cumulative analysis revealed that radioembolization with yttrium-90 conferred tumour control rate in 81% of patients. Overall survival post-radioembolization ranged from 3.6 to 20.9 mo with an estimated mean survival of 11.3 mo.
Conclusion: Radioembolization with ytrrium-90 appears to confer control of tumour growth rate in most patients, however its effect on patient survival need to be elucidated further. Furthermore, quality evidence in the form of randomized trials is needed in order to assess the effect of radioembolization in more depth.
Keywords: Breast cancer; Liver metastases; Radioembolization; Survival; Yttrium-90.
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Figures
Similar articles
-
A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma.Eur J Radiol. 2017 Jul;92:111-115. doi: 10.1016/j.ejrad.2017.05.005. Epub 2017 May 4. Eur J Radiol. 2017. PMID: 28624008 Review.
-
Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.JBI Libr Syst Rev. 2005;3(6):1-33. doi: 10.11124/01938924-200503060-00001. JBI Libr Syst Rev. 2005. PMID: 27819973
-
Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.Eur J Radiol. 2018 Mar;100:23-29. doi: 10.1016/j.ejrad.2018.01.012. Epub 2018 Jan 9. Eur J Radiol. 2018. PMID: 29496075 Review.
-
90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.J Nucl Med. 2016 May;57(5):665-71. doi: 10.2967/jnumed.115.166082. Epub 2015 Dec 3. J Nucl Med. 2016. PMID: 26635340
-
KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.J Vasc Interv Radiol. 2015 Aug;26(8):1102-11. doi: 10.1016/j.jvir.2015.05.032. J Vasc Interv Radiol. 2015. PMID: 26210240 Clinical Trial.
Cited by
-
Impact of Hypoxia on Radiation-Based Therapies for Liver Cancer.Cancers (Basel). 2024 Feb 22;16(5):876. doi: 10.3390/cancers16050876. Cancers (Basel). 2024. PMID: 38473237 Free PMC article. Review.
-
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).Cardiovasc Intervent Radiol. 2022 Nov;45(11):1725-1734. doi: 10.1007/s00270-022-03254-4. Epub 2022 Aug 25. Cardiovasc Intervent Radiol. 2022. PMID: 36008574
-
Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study.Adv Radiat Oncol. 2021 Oct 29;7(1):100838. doi: 10.1016/j.adro.2021.100838. eCollection 2022 Jan-Feb. Adv Radiat Oncol. 2021. PMID: 35071835 Free PMC article.
-
The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis.Bioengineered. 2021 Dec;12(2):12246-12262. doi: 10.1080/21655979.2021.2006552. Bioengineered. 2021. PMID: 34783637 Free PMC article.
-
Successful treatment with yttrium-90 microspheres in a metastatic breast cancer patient and sclerosing cholangitis.Future Sci OA. 2021 Jun 4;7(7):FSO716. doi: 10.2144/fsoa-2021-0015. eCollection 2021 Aug. Future Sci OA. 2021. PMID: 34258025 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
-
- Eichbaum MH, Kaltwasser M, Bruckner T, de Rossi TM, Schneeweiss A, Sohn C. Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat. 2006;96:53–62. - PubMed
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. - PMC - PubMed
-
- Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5:773–782. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous